|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, two other genes, BCL6 and BCL2, which are classically related to apoptosis and non-Hodgkin lymphoma, were shown for the first time to be involved in amplification.
|
15611930 |
2005 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We have recently reported that Rituximab (anti-CD20) sensitizes drug-resistant 2F7 and 10C9 B Non-Hodgkin's lymphoma (NHL) cell lines to the apoptotic effects of various chemotherapeutic drugs by downregulation of IL-10 and Bcl-2 expression.
|
15077178 |
2004 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
|
15651174 |
2004 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Incidence of BCL-2 gene rearrangements in Argentinean non-Hodgkin lymphoma patients: increased frequency of breakpoints outside of MBR and MCR.
|
14757440 |
2004 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
This study assessed the induction of apoptosis of acute lymphoblastic leukaemia (ALL) and non-Hodgkin's lymphoma (NHL) blastic cells following in vitro treatment with dexamethasone (DXM), vincristine (VCR), and tumour necrosis factor (TNF) in relation to the expression of bcl-2 and p-gp.
|
11855781 |
2001 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The t(14;18) translocation is a common somatic mutation in non-Hodgkin's lymphoma (NHL) that is associated with bcl-2 activation and inhibition of apoptosis.
|
11679800 |
2001 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
The NHL was considered a histological conversion from follicular lymphoma because lymphoma cells carried t(14;18) (q32;q21) and were strongly positive for BCL2 protein.
|
10700860 |
2000 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical studies supported the diagnosis of NHL in both cases; the neoplasms were positive for CD20 and BCL-2 and negative for CD3.
|
10631864 |
2000 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Twenty-one patients with Bcl-2-positive relapsed NHL received a 14-day subcutaneous infusion of G3139, an 18-mer phosphorothioate oligonucleotide complementary to the first six codons of the bcl-2 open reading frame.
|
10784621 |
2000 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.
|
10873104 |
2000 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This study was planned with the aim to investigate the association between bcl-2 gene rearrangements and apoptotic changes during chemotherapy in patients with non-Hodgkin's lymphoma.
|
10074891 |
1999 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The purpose of the present study was to investigate the possibility of similar correlation between bcl-2 expression and EBV infection in vivo in a cohort of patients with aggressive NHL, who were uniformly evaluated and treated with effective chemotherapy.
|
10794603 |
1999 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Fifty-one cases of intestinal non-Hodgkin's lymphoma (NHL) (10 small B-cell mucosa-associated lymphoid tissue [MALT] NHLs, 12 large B-cell MALT NHLs, 18 large B-cell NHLs, 2 small T-cell NHLs, 7 large T-cell NHLs, and 2 mantle cell NHLs) were studied for the immunohistochemical expression of MIB-1 and the TUNEL assay as well as the expression of bcl-2 and p53, both of which are regulatory gene products involved in apoptosis.
|
9655306 |
1998 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The t(14;18)(q32;q21) translocation, involving the BCL2 gene and junctional segments (JH) of the immunoglobulin heavy chain gene (IGH), constitutes the most common chromosomal translocation in non-Hodgkin's lymphoma of B-cell type.
|
9443038 |
1998 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
The inverse relationship between BCL-2 expression and proliferative activity in the intermediate- and high-grade NHLs is consistent with recent studies suggesting that Bcl-2 both retards entry into the cell cycle and inhibits apoptosis.
|
9454770 |
1998 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
To accurately measure the number of non-Hodgkin's lymphoma (NHL) cells harboring the bcl-2/immunoglobulin H (IgH) rearrangement in progenitor cell grafts, we developed a nested quantitative competitive polymerase chain reaction assay (QC-PCR).
|
9414302 |
1998 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, in another series of 11 patients and a NHL cell line, we demonstrated t(14;18) and t(11;14) in interphase and metaphase cells with a combination of BCL2 (or PRAD1) with IgH gene probes.
|
9209369 |
1997 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The presence of a bcl-2 gene rearrangement in de novo DLCL suggests a possible follicle center cell origin and perhaps a distinct clinical behavior more akin to low-grade non-Hodgkin's lymphoma (NHL).
|
9207459 |
1997 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Other studies have suggested an inverse relationship between p53 and bcl-2 protein expression in breast and colonic cancers and in a variety of subtypes of non-Hodgkin's lymphoma.
|
9349233 |
1997 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study suggests that BCL6 rearrangement is primarily associated with large cell lymphoma, and that BCL2(-)BCL6(+) NHL could potentially be curable with modern combination chemotherapy.
|
9209377 |
1997 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results indicate an IGL-mediated rearrangement of an unknown gene at 9q34 that together with BCL2 and MYC might be involved in the lymphomagenesis of the present case of FCCL and perhaps in other cases of non-Hodgkin lymphoma in which t(9;22) is sporadically occurring.
|
9331562 |
1997 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Survival curves suggested that NHL carrying rearrangement of BCL6 and lacking that of BCL2 is curable by chemotherapy.
|
9373196 |
1997 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
BCL-2 antisense therapy in patients with non-Hodgkin lymphoma.
|
9113013 |
1997 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In order to clarify the effects of Epstein-Barr virus (EBV) infection on apoptosis and proliferative activity of non-Hodgkin's lymphoma, 135 Japanese lymphoma cases were investigated for the presence of viral RNA and its correlation with bcl-2 protein (Bcl-2) expression.
|
9260592 |
1997 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
NHL is commoner in men than in women, and our data indicate a trend toward higher bcl2 mutagenesis in males than females.
|
9020305 |
1997 |